Fig. 5: Changes in immune cell composition in the TME associated with pembrolizumab sensitivity. | Nature Communications

Fig. 5: Changes in immune cell composition in the TME associated with pembrolizumab sensitivity.

From: Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

Fig. 5

A Top 10 enriched down-regulated and up-regulated Gene Ontology Biological Processes from genes differentially regulated by pembrolizumab in treatment-sensitive compared to treatment-insensitive tumors. B Comparison of change in immune cell abundance in the TME at cycle 3 of pembrolizumab treatment between sensitive and insensitive tumors. The median for each group is marked by a horizontal black line in the center of a rectangle and data points are shown as open circles. The distance between the third-quartile (Q3) and first-quartile (Q1), known as the interquartile range (IQR), is marked around the median by a rectangle. Vertical lines extending from the top and bottom of the rectangle show the maximum (Q3 + 1.5-times IQR) and minimum (Q1 + 1.5-times IQR). P-values were calculated by two-sided Wilcoxon rank-sum tests. C. Kaplan-Meier plot of progression-free survival in patients stratified by increase or decrease in Tfh score from baseline. (p = 0.0007). P-values reflect the outcomes of a two-sided log-rank test of a univariate Cox proportional hazards model. Source data are provided in SourceData_Fig5.xlsx. TME tumor microenvironment.

Back to article page